Epoetin theta showed no clear difference in adverse events: discontinuation of therapy compared with epoetin beta (low certainty).
Epoetin alpha every 2 weeks may leads to lower number reaching target Hb compared with to weekly (low certainty).
Epoetin alpha every 2 weeks showed no clear difference in number of deaths compared with to weekly (low certainty).
Epoetin alpha every 2 weeks showed no clear difference in adverse events: RBC transfusions compared with to weekly (low certainty).
Epoetin alpha every 2 weeks showed no clear difference in adverse events: hypertension compared with to weekly (moderate certainty).
Epoetin alpha every 2 weeks showed no clear difference in adverse events: thrombovascular events compared with to weekly (low certainty).
It is very uncertain whether epoetin alfa every four weeks changes number reaching target Hb compared with with every two weeks (very low certainty).
Epoetin alfa every four weeks showed no clear difference in number of deaths compared with with every two weeks (low certainty).
Antiplatelet agents probably leads to lower fatal or nonfatal myocardial infarction compared with control (moderate certainty).
It is very uncertain whether antiplatelet agents changes fatal or nonfatal stroke compared with control (very low certainty).
Antiplatelet agents showed no clear difference in death (any cause) compared with control (low certainty).
It is very uncertain whether antiplatelet agents changes cardiovascular death compared with control (very low certainty).
Antiplatelet agents probably leads to higher major bleeding compared with control (moderate certainty).
Antiplatelet agents may leads to higher minor bleeding compared with control (low certainty).
Antiplatelet agents may leads to lower early access thrombosis (before 8 weeks) compared with control (low certainty).
Oral cyclophosphamide showed no clear difference in complete remission: all renal pathologies compared with prednisone or placebo (low certainty).
Oral cyclophosphamide showed no clear difference in complete remission: FSGS compared with prednisone or placebo (low certainty).
Oral cyclophosphamide showed no clear difference in complete or partial remission compared with prednisone or placebo (low certainty).
Oral cyclophosphamide showed no clear difference in complete or partial remission: FSGS compared with prednisone or placebo (low certainty).